Key clinical point: Dipeptidyl peptidase 4 inhibitors (DPP-4i), but not glucagon-like peptide 1 receptor agonists (GLP-1 RA), significantly increased the risk for acute liver injury in patients with type 2 diabetes (T2D) compared with sodium-glucose cotransporter-2 inhibitors (SGLT-2i).
Major finding: Compared with SGLT-2i, DPP-4i (hazard ratio [HR] 1.53; 95% CI 1.02-2.30), but not GLP-1 RA (HR 1.11; 95% CI 0.57-2.16), were associated with a higher risk for acute liver injury; however, the risk was significantly higher in women receiving DPP-4i (HR 3.22; 95% CI 1.67-6.21) and GLP-1 RA (HR 3.23; 95% CI 1.44-7.25).
Study details: Findings are from a population-based study including 2 new-user, active-comparator cohorts; the first cohort included 106,310 and 27,277 new users of DPP-4i and SGLT-2i, respectively, and the second cohort included 9470 and 26,936 new users of GLP-1 RA and SGLT-2i, respectively.
Disclosures: This study was funded by a Canadian Institutes of Health Research Foundation Scheme grant. L Azoulay declared receiving consulting fees from Janssen Pharmaceuticals and Pfizer outside this work.
Source: Pradhan R et al. Incretin-based drugs and the risk of acute liver injury among patients with type 2 diabetes. Diabetes Care. 2022 (Jul 22). Doi: 10.2337/dc22-0712